Beyond the Numbers: A Holistic Approach to Minimal Residual Disease Market Research for Sustainable Revenue

ishadeshpande

New Member
Joined
Dec 29, 2023
Messages
16
Karma
0
Car
BMW
The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the forecast period, according to the latest analysis by Emergen Research. Rising R&D activities and increase in research funding from various cancer institutes are major factors projected to support market revenue growth between 2021 and 2030. For instance, Invitae Corporation, based in the U.S., started a research in February 2022 to collect actual data on tailored minimal residual disease diagnostics for distinct tumor types. Inivata also introduced RaDaR assay in April 2020 to identify and track residual disease and relapse in plasma samples of patients with prior cancer diagnoses. In addition, RaDaR assay is based on next-generation sequencing platform InVision liquid biopsy, developed by Inivata, which has built-in control and error checking for highly sensitive and precise variant detection. Moreover, to improve testing and detection outcomes, companies competing in the worldwide MRD testing market are concentrating more on disease-specific and tailored diagnostic kits, which is also expected to drive revenue growth of the market.
The report titled ‘Global Minimal Residual Disease Market’ provides the reader with a panoramic view of the Minimal Residual Disease industry while estimating the overall size and the size and share of the market’s key regional segments over the projected timeframe. According to our market analysts, the global Minimal Residual Disease market is expected to exhibit a robust growth rate throughout the forecast period. The promising market growth can be attributed to the significant rise in product demand across the regional markets.
Request a Sample Report with Table of Contents and Figures to click Here: https://www.emergenresearch.com/request-sample/1352
Competitive Terrain:

The section on the competitive landscape offers valuable and actionable insights related to the business sphere of the Minimal Residual Disease market, covering extensive profiling of the key market players. The report offers information about market share, product portfolio, pricing analysis, and strategic alliances such as mergers and acquisitions, joint ventures, collaborations, partnerships, product launches and brand promotions, among others. The report also discusses the initiatives taken by the key companies to combat the impact of the COVID-19 pandemic.
The leading market contenders listed in the report are:
Adaptive Biotechnologies, ARUP Laboratories, Bio-Rad Laboratories, Inc., Cergentis B.V., F. Hoffmann-La Roche Ltd., ICON Plc, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Mission Bio, Natera, Inc., NeoGenomics Laboratories, OPKO Health, Inc., and Sysmex Corporation
Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/minimal-residual-disease-market
Emergen Research has segmented the global Minimal Residual Disease market on the basis of type, application, end-use, and region:
Segments Covered in this report are:

  • Indication Outlook (Revenue, USD Million; 2019–2030)
    • Leukemia
      1. Acute Lymphoblastic Leukemia (ALL)
      2. Chronic Lymphoblastic Leukemia (CLL)
      3. Acute Myeloid Leukemia (AML)
      4. Chronic Myeloid Leukemia (CML)
      5. Others
    • Lymphoma
      1. Non-Hodgkin’s Lymphoma (NHL)
      2. Marginal Zone Lymphoma
      3. Follicular Lymphoma
      4. Peripheral T-cell Lymphoma
      5. Mantle Cell Lymphoma
      6. Others
    • Multiple Myeloma (MM)
    • Solid Tumor
    • Others
  • Detection Outlook (Revenue, USD Million; 2019–2030)
    • Next-Generation Sequencing (NGS)
    • Flow Cytometry
    • Polymerase Chain Reaction (PCR)
    • Fluorescence In-Situ Hybridization (FISH)
    • Others
  • Treatment Methods Outlook (Revenue, USD Million; 2019–2030)
    • Chemotherapy
    • Stem Cell Transplant
    • CAR-T Cell Therapy
    • Others
The various regions analyzed in the report include:
  • North America (U.S., Canada)
  • Europe (U.K., Italy, Germany, France, Rest of EU)
  • Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
  • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Key Objectives of the Report:
  • Analysis and estimation of the Minimal Residual Disease Market size and share for the projected period of 2022-2030
  • Extensive analysis of the key players of the market by SWOT analysis and Porter’s Five Forces analysis to impart a clear understanding of the competitive landscape
  • Study of current and emerging trends, restraints, drivers, opportunities, challenges, growth prospects, and risks of the global Minimal Residual Disease Market
  • Analysis of the growth prospects for the stakeholders and investors through the study of the promising segments
  • Strategic recommendations to the established players and new entrants to capitalize on the emerging growth opportunities
Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-history/1352
Latest Published Reports by Emergen Research:

product information management market
https://www.emergenresearch.com/industry-report/product-information-management-market
geospatial analytics market
https://www.emergenresearch.com/industry-report/geospatial-analytics-market
wireless earbuds market
https://www.emergenresearch.com/industry-report/wireless-earbuds-market
business transcription market
https://www.emergenresearch.com/industry-report/business-transaction-market
antibody-drug conjugates market
https://www.emergenresearch.com/industry-report/antibody-drug-conjugates-market
 

Latest threads

Top